Heidelberg Epignostix GmbH
Heidelberg Epignostix develops precision cancer diagnostics through DNA methylation profiling and machine learning algorithms for accurate tumor classification. This technology enhances diagnostic accuracy, enabling healthcare providers to make informed decisions regarding cancer treatment and management.
- Artificial Intelligence
- Digital Health
- Healthcare Technology
- Software Only
Funding
Raised to date
$4.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
- lbbwvc.de (opens in a new tab)investor website
Founders
Product
Problem
Accurate and precise diagnosis is crucial for optimal management of patients with cancer, but current methods for tumor classification can be inaccurate. This can lead to suboptimal treatment decisions and outcomes for cancer patients.
Solution
Heidelberg Epignostix is developing software solutions for precision molecular diagnostics, leveraging DNA methylation profiling and machine learning for accurate tumor classification. Their technology aims to improve diagnostic accuracy, enabling healthcare providers to make more informed decisions regarding cancer treatment and management. By combining scientific and medical expertise with technical innovation, Heidelberg Epignostix seeks to personalize cancer treatments.
Target Audience
The primary audience includes healthcare providers and oncologists involved in cancer diagnosis, treatment, and management.
Features
- Molecular tumor classification based on DNA methylation profiling.
- Machine learning algorithms for enhanced diagnostic accuracy.
- Software solutions for clinical use.